* Emerging from an abnormal regulatory downturn as European carbon markets normalise and US profitability accelerates
* BUY: FY25/26p confirms the earnings turnaround, while further US ramp-up, GHG quota monetisation and renewable chemicals provide additional earnings and cash flow upside
LÄS MER